Background
Artificial Intelligence (“AI”) has been utilized by innovative companies across the array of industry spaces, but its impact on biotech (and human health in general) could become the most significant among all sectors.
AI is being leveraged across the drug development spectrum to accelerate inherently burdensome tasks including the identification of targets and leads,
Introduction: Harnessing Cellular Machinery for Precision Medicine
Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and successful advancements in the field of targeted protein degradation, leaving intellectual property (IP) protections and strategies in hot pursuit. Unlike traditional inhibitors, which only
The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is no exception.
AI-driven platforms have become increasingly useful to biotech innovators in many areas including in discovering and developing drugs. For example, a 2022 article by McKinsey & Company estimated that nearly 270 companies have
The Unted States Patent and Trademark Office (USPTO) recently published new guidance on subject-matter eligibility as related to Artificial Intelligence (AI), opening a written comment window to respond with a deadline of September 16, 2024. The guidance was brought about by an October 2023 Executive Order on the “Safe, Secure, and Trustworthy Development and
The alternative (“alt-“) animal products industry is growing increasingly more popular each year, causing an increased demand in foods made from plant proteins or cultured in a lab. As more alt-animal products emerge, the amount of foodtech patents increases and the foodtech patent landscape becomes more and more complex. In this article, we will provide